227 related articles for article (PubMed ID: 17685560)
1. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells.
Pickhardt M; Larbig G; Khlistunova I; Coksezen A; Meyer B; Mandelkow EM; Schmidt B; Mandelkow E
Biochemistry; 2007 Sep; 46(35):10016-23. PubMed ID: 17685560
[TBL] [Abstract][Full Text] [Related]
2. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments.
Jeganathan S; von Bergen M; Mandelkow EM; Mandelkow E
Biochemistry; 2008 Oct; 47(40):10526-39. PubMed ID: 18783251
[TBL] [Abstract][Full Text] [Related]
3. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping.
Larbig G; Pickhardt M; Lloyd DG; Schmidt B; Mandelkow E
Curr Alzheimer Res; 2007 Jul; 4(3):315-23. PubMed ID: 17627489
[TBL] [Abstract][Full Text] [Related]
4. Possible role of each repeat structure of the microtubule-binding domain of the tau protein in in vitro aggregation.
Tomoo K; Yao TM; Minoura K; Hiraoka S; Sumida M; Taniguchi T; Ishida T
J Biochem; 2005 Oct; 138(4):413-23. PubMed ID: 16272135
[TBL] [Abstract][Full Text] [Related]
5. Structural impact of heparin binding to full-length Tau as studied by NMR spectroscopy.
Sibille N; Sillen A; Leroy A; Wieruszeski JM; Mulloy B; Landrieu I; Lippens G
Biochemistry; 2006 Oct; 45(41):12560-72. PubMed ID: 17029411
[TBL] [Abstract][Full Text] [Related]
6. Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain.
Barghorn S; Davies P; Mandelkow E
Biochemistry; 2004 Feb; 43(6):1694-703. PubMed ID: 14769047
[TBL] [Abstract][Full Text] [Related]
7. Disaggregation of tau as a therapeutic approach to tauopathies.
Duff K; Kuret J; Congdon EE
Curr Alzheimer Res; 2010 May; 7(3):235-40. PubMed ID: 20088807
[TBL] [Abstract][Full Text] [Related]
8. Molecules of the quinoline family block tau self-aggregation: implications toward a therapeutic approach for Alzheimer's disease.
Navarrete LP; Guzmán L; San Martín A; Astudillo-Saavedra L; Maccioni RB
J Alzheimers Dis; 2012; 29(1):79-88. PubMed ID: 22232002
[TBL] [Abstract][Full Text] [Related]
9. Development of tau aggregation inhibitors for Alzheimer's disease.
Bulic B; Pickhardt M; Schmidt B; Mandelkow EM; Waldmann H; Mandelkow E
Angew Chem Int Ed Engl; 2009; 48(10):1740-52. PubMed ID: 19189357
[TBL] [Abstract][Full Text] [Related]
10. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells.
Pickhardt M; Gazova Z; von Bergen M; Khlistunova I; Wang Y; Hascher A; Mandelkow EM; Biernat J; Mandelkow E
J Biol Chem; 2005 Feb; 280(5):3628-35. PubMed ID: 15525637
[TBL] [Abstract][Full Text] [Related]
11. Granular tau oligomers as intermediates of tau filaments.
Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
[TBL] [Abstract][Full Text] [Related]
12. X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease.
Sevcik J; Skrabana R; Dvorsky R; Csokova N; Iqbal K; Novak M
FEBS Lett; 2007 Dec; 581(30):5872-8. PubMed ID: 18061582
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's-disease-associated conformation of intrinsically disordered tau protein studied by intrinsically disordered protein liquid-phase competitive enzyme-linked immunosorbent assay.
Skrabana R; Skrabanova-Khuebachova M; Kontsek P; Novak M
Anal Biochem; 2006 Dec; 359(2):230-7. PubMed ID: 17081491
[TBL] [Abstract][Full Text] [Related]
15. Understanding the disrupting mechanism of the Tau aggregation motif "
Moreno-Castillo E; Álvarez-Ginarte YM; Valdés-Tresanco ME; Montero-Cabrera LA; Moreno E; Valiente PA
J Mol Recognit; 2020 Sep; 33(9):e2848. PubMed ID: 32227525
[TBL] [Abstract][Full Text] [Related]
16. Tau aggregation followed by atomic force microscopy and surface plasmon resonance, and single molecule tau-tau interaction probed by atomic force spectroscopy.
Barrantes A; Sotres J; Hernando-Pérez M; Benítez MJ; de Pablo PJ; Baró AM; Avila J; Jiménez JS
J Alzheimers Dis; 2009; 18(1):141-51. PubMed ID: 19625749
[TBL] [Abstract][Full Text] [Related]
17. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases.
Necula M; Chirita CN; Kuret J
Biochemistry; 2005 Aug; 44(30):10227-37. PubMed ID: 16042400
[TBL] [Abstract][Full Text] [Related]
18. Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation.
Santa-María I; Hernández F; Moreno FJ; Avila J
Neurosci Lett; 2007 Dec; 429(2-3):91-4. PubMed ID: 17976912
[TBL] [Abstract][Full Text] [Related]
19. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS.
Ma Q; Li Y; Du J; Liu H; Kanazawa K; Nemoto T; Nakanishi H; Zhao Y
Peptides; 2006 Apr; 27(4):841-9. PubMed ID: 16225961
[TBL] [Abstract][Full Text] [Related]
20. Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity.
Zhang YJ; Xu YF; Chen XQ; Wang XC; Wang JZ
FEBS Lett; 2005 Apr; 579(11):2421-7. PubMed ID: 15848182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
